TOPLUM VE HASTANE KAYNAKLI İNFEKSİYONLARDAN İZOLE ...

In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial
Agents and Chemotherapy, Chicago, IL, 2003. Abstract 3464, p. 206–207. American Society
for Microbiology, Washington, DC, USA.
43 -Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new
glycylcycline. Clin Microbiol Infect 2000; 6: 159–63
44-Goldstein EJ, Citron DM, Merriam CV et al. Comparative in vitro activities of GAR-936
against aerobic and anaerobic animal and humanbite wound pathogens. Antimicrob Agents
Chemother 2000; 44: 2747–51.
45- Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents,including
gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn
Microbiol Infect Dis 2002; 42: 145–7.
46. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 againstChlamydia
pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16: 61–3.
47-R.Fernandez-Roblas, N.Z Martin-de Hijas,A.I.Fernandez-Martinez,D Garcia-
Almeida.I.Gadea .J. Esteban.İn vitro Activites of Tigecycline and 10 other Antimicrobials
against Nonpigmented Rapidly Growing Mycobacteria.Antimicrobial Agents and
Chemotherapy,Now,2008,p,4184-4186
48- Clinical and Laboratory Standards Institute (Formerly NCCLS). Performance Standards
for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement (M100-S18),
January 2008.
49-EARSSAnnualReport2007:146-147 [http://www.rivm.nl/earss/result/Monitoring_reports/].
50- EARSS Annual Report 2007: 58-67 [http://www.rivm.nl/earss/result/Monitoring_reports/
51- İdris ŞAHİN, Demet KAYA, Şükrü ÖKSÜZ, Aynur OKAY, İrfan ŞENCAN, Elif
ÖZTÜRK. Klinik örneklerden izole edilen Gram negatif çomaklarda geniş spektrumlu betalaktamaz
sıklığı ve antibiyotik duyarlılığı. İ nfeksiyon Dergisi (Turkish Journal of Infection)
2003; 17 (1): 45-48
64